Paricalcitol. Vitamin D analog, treatment for hyperparathyroidism

Drugs of the Future

Volumn 23, Issue 6, 1998, Pages 602-606

  Graul, A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

AREA UNDER THE CURVE; CALCIUM TRANSPORT; CLINICAL TRIAL; DRUG ELIMINATION; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 3543012537     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.06.461708     Document Type: Review

References (15)

1. DeLuca, H.F., Schnoes, H.K., Hamer, D.E., Paaren, H.E. (Wisconsin Alumni Res. Found.). Process for preparing 1α-hydroxylated cpds. US 4195027.
2. DeLuca, H.F., Schnoes, H.K., Perlman, K.L., Sicinski, R.R., Prahl, J.M. (Wisconsin Alumni Res. Found.). 19-Nor vitamin D cpds. EP 387077, JP 91505330, US 5246925, WO 9010620.
3. DeLuca, H.F., Schnoes, H.K., Perlman, K.L., Sicinski, R.R., Prahl, J.M. (Wisconsin Alumni Res. Found.). 19-Nor-vitamin D cpds. US 5587497.
4. Prous, J.R. Thyroid disease therapy. In: The Year's Drug News - Therapeutic Targets, 1995 Edition, Prous Science Publishers, 1995, 349.
5. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Amer J Kidney Dis 1997, 30: 105-12.
6. 2): A new vitamin D drug for renal osteodystrophy. 10th Workshop Vitamin D (May 24-29, Strasbourg) 1997, 215.
7. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Amer J Kidney Dis 1995, 26: 852-60.
8. 2 on calcium and phosphate resorption in bone. J Amer Soc Nephrol 1997, 8: Abst A2669.
9. 3, on the parathyroid glands. J Amer Soc Nephrol 1997, 8: Abst A2660.
10. 2 supppresses immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim Biophys Acta 1993, 1158: 279-86.
11. Cato, A. III, Qasawa, B., Chang, M., Soltanek, C., Stoll, R., Cady, W. Lack of effect of hemodialysis on plasma concentrations of 19-nor-1α,25-dihydroxy-vitamin D2 (19-nor) allows dose administration without regard to dialysis. J Amer Soc Nephrol 1997, 8: Abst A2661.
12. Cato, A. III, Buschen, C., Ahmed, A., Chang, M., Lanni, C., Amdahl, M., Klemz, M., Stoll, R. The pharmacokinetics of paracalcin. Clin Pharmacol Ther 1997, 61(2): Abst PIII-95.
13. ™ for suppression of parathyroid hormone in chronic renal failure patients. Abbott Laboratories Press Release 1998, April 23.
14. ™ (paricalcitol injection). Abbott Laboratories Product Insert 1998, April.
15. Abbott introduces new drug for hyperparathyroidism in U.S. Prous Science Daily Essentials May 15, 1998.